If approved, ISL/LEN could become the first once-weekly, single-tablet HIV treatment to reach the market as patients rely on once-daily options.
The results of two phase 3 trials suggest that investigational drug bepirovirsen reduces HBsAg production, helping the immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results